Senior Associate

CI is Connecticut’s strategic venture capital arm and one of the most active early-stage investors on the eastern seaboard. CI has a portfolio of 250+ companies across 5 equity funds and a 1 venture debt fund. We have $550 million in assets under management, and our venture portfolio employs 4,000 jobs. In a typical year, we deploy $50 million and write between 60-80 checks.

We review 750 companies per year and invite over 100 founders in to pitch us each year.

We add 30 new companies to our portfolio annually, and we also invest as an LP in Connecticut-based venture capital funds.

We measure success through both financial returns and economic impact, including job creation. Over the past decade, CI has generated more than $400 million in returns and cumulatively, our portfolio companies have raised over $8 billion.

• Fiscal 2026 was our best year on record. We generated $76.1 million in cash proceeds from all investment activities. Most of those proceeds came from our strong New Haven bioscience sector. In FY26 actuals, we invested $59.3 million into 75 early-stage companies and venture funds, and those deals pulled an additional $1.2 billion of outside capital into the state.
• As of July 2026, CI earned the #1 spot in New England for portfolio exit value and ranked among top 5 East Coast venture firms investing at the Series B stage or earlier.
  Over the past 365 days, CI generated more than $125 million in cash returns
  .

Our culture is vibrant, diverse, collaborative, and inclusive. We embrace perspective and have mission alignment on our impact to Connecticut's innovation ecosystem.

CBIF is a $200 million fund that deploys equity and loans to move bioscience breakthroughs to market faster. The portfolio spans more than 100 companies across therapeutics, biotech, diagnostics, medical devices, life science tools and digital health. Since 2013 our bioscience investment activity has more than doubled, and the portfolio has leveraged $3.5+ billion in outside capital.

In November 2025, Johnson & Johnson announced its acquisition of Halda Therapeutics for approximately $3.05 billion in cash.

Just three months later, in February 2026, New Haven’s Veradermics raised $256.3 million in its IPO, with market cap today exceeding $4 billion. In April, its lead candidate, VDPHL
01, posted positive Phase 2/3 topline results, meeting all primary and key secondary endpoints.

• Recent bioscience IPOs
  :
  Arvinas, Biohaven Pharmaceuticals, Rally Bio, Sema4, Veradermics.
• Recent bioscience acquisitions
  :
  Avitus, Biorez, Dia Imaging Analysis, Diameter Health, Halda Therapeutics, Medically Home, Modifi Bio, Populi.

The CBIF Venture Team is a small team. Each team member plays a pivotal role as part of the investment due diligence process and post-investment, as part of scaling the portfolio company. It is a team that embraces diversity of thought, listens with an open mind, thinks big and concretely, and invests with the mission in mind.

This is a unique hands-on venture capital experience in an innovative and collaborative work environment. This opportunity to contribute, add value, and make an economic impact in the State of Connecticut is extraordinary. We seek an absolutely elite team member to hit the ground sprinting.

Team members play a key role in executing our investment strategy by researching and cultivating promising investment opportunities and participating in all phases of the investment process including sourcing, due diligence, meetings with management, focused company and industry research, financial modeling, writing investment recommendations. Post-investment, team members monitor the portfolio company and support the business’…